Morgan Stanley set a $15.00 target price on Teva Pharmaceutical Industries Limited (NYSE:TEVA) in a research note issued to investors on Thursday. The firm currently has an underweight rating on the stock.

Other equities research analysts also recently issued reports about the stock. Mizuho raised shares of Teva Pharmaceutical Industries Limited from a neutral rating to a buy rating and upped their price target for the company from $25.00 to $30.00 in a report on Thursday, June 15th. Royal Bank Of Canada set a $38.00 price target on shares of Teva Pharmaceutical Industries Limited and gave the company a buy rating in a report on Friday, June 16th. Oppenheimer Holdings, Inc. set a $41.00 price target on shares of Teva Pharmaceutical Industries Limited and gave the company a buy rating in a report on Tuesday, June 27th. BidaskClub upgraded Teva Pharmaceutical Industries Limited from a hold rating to a buy rating in a report on Wednesday, July 5th. Finally, Vetr upgraded Teva Pharmaceutical Industries Limited from a hold rating to a buy rating and set a $32.27 price objective on the stock in a report on Tuesday, July 11th. Five investment analysts have rated the stock with a sell rating, eighteen have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of Hold and an average target price of $27.63.

Teva Pharmaceutical Industries Limited (NYSE TEVA) opened at 15.94 on Thursday. The firm’s 50-day moving average is $16.91 and its 200 day moving average is $26.76. Teva Pharmaceutical Industries Limited has a 12-month low of $15.22 and a 12-month high of $45.85. The stock’s market capitalization is $16.20 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The business had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.72 billion. During the same period in the previous year, the company posted $1.25 earnings per share. Teva Pharmaceutical Industries Limited’s revenue was up 12.9% compared to the same quarter last year. Equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.27 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/10/09/teva-pharmaceutical-industries-limited-teva-pt-set-at-15-00-by-morgan-stanley.html.

The business also recently announced a quarterly dividend, which was paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th were given a dividend of $0.085 per share. The ex-dividend date was Friday, August 25th. This represents a $0.34 dividend on an annualized basis and a yield of 2.13%. Teva Pharmaceutical Industries Limited’s payout ratio is currently -15.36%.

A number of institutional investors have recently made changes to their positions in TEVA. Capital Research Global Investors boosted its position in Teva Pharmaceutical Industries Limited by 13.8% during the second quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock worth $2,535,518,000 after purchasing an additional 9,260,426 shares during the period. Franklin Resources Inc. boosted its position in Teva Pharmaceutical Industries Limited by 11.1% during the second quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock worth $2,218,958,000 after purchasing an additional 6,685,844 shares during the period. FMR LLC boosted its position in Teva Pharmaceutical Industries Limited by 16.7% during the second quarter. FMR LLC now owns 42,844,979 shares of the company’s stock worth $1,423,310,000 after purchasing an additional 6,115,853 shares during the period. Capital World Investors boosted its position in Teva Pharmaceutical Industries Limited by 41.9% during the second quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock worth $367,686,000 after purchasing an additional 3,268,200 shares during the period. Finally, Alliancebernstein L.P. boosted its position in Teva Pharmaceutical Industries Limited by 32.3% during the second quarter. Alliancebernstein L.P. now owns 11,399,400 shares of the company’s stock worth $378,688,000 after purchasing an additional 2,782,257 shares during the period. 56.75% of the stock is owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.